echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > CStone Announces The Lancet-Oncology Announcement of a Phase III Registration Clinical Study of Zejima(R) (Sugalimab Injection) in the Treatment of Non-Small Cell Lung Cancer

    CStone Announces The Lancet-Oncology Announcement of a Phase III Registration Clinical Study of Zejima(R) (Sugalimab Injection) in the Treatment of Non-Small Cell Lung Cancer

    • Last Update: 2022-01-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>


    The GEMSTONE-301 study was designed to evaluate the efficacy and safety of Zejimet® as consolidation therapy in patients with unresectable stage III non-small cell lung cancer (NSCLC) who have not progressed after concurrent or sequential chemoradiotherapy


    The GEMSTONE-301 study met the prespecified primary endpoint in a planned interim analysis


    Professor Wu Yilong, the principal investigator of the GEMSTONE-301 study, the corresponding author of the article, and the Guangdong Provincial People's Hospital, said: "The publication of the GEMSTONE-301 study in The Lancet-Oncology demonstrates that Chinese researchers have successfully explored and developed a broad scientific perspective.


    Jianxin Yang, Chief Medical Officer of CStone, said: "The Lancet-Oncology, as an authoritative professional publication in oncology, has been focusing on major progress in improving the status of global tumor prevention and control, publishing high-quality research results on tumor control and treatment.


    Recently, the National Medical Products Administration (NMPA) of China has approved the New Drug Application of Zejimei® for the first-line treatment of patients with squamous or non-squamous stage IV non-small cell lung cancer in combination with chemotherapy


    About Zejimet® (Sugalimumab Injection)

    Zejimet® is an investigational anti-PD-L1 monoclonal antibody independently developed by CStone


    At present, the National Medical Products Administration of China has approved the New Drug Application of Zejimet® for the combination of pemetrexed and carboplatin for epidermal growth factor receptor (EGFR) gene mutation-negative and anaplastic lymphoma kinase (ALK) First-line treatment of patients with negative metastatic non-squamous non-small cell lung cancer, and combination paclitaxel and carboplatin for first-line treatment of patients with metastatic squamous non-small cell lung cancer


    About the GEMSTONE-301 Study

    GEMSTONE-301 is a multicenter, randomized, double-blind phase III clinical trial (clinicaltrials.


    In May 2021, the GEMSTONE-301 study met the prespecified primary endpoint as assessed by an independent data monitoring committee (iDMC) at a planned interim analysis


    In September 2021, the National Medical Products Administration of China has accepted the NDA of Zejimet® for the treatment of stage III NSCLC indications for the treatment of unresectable stage III non-small cell non-small cell disease without disease progression after concurrent or sequential chemoradiotherapy lung cancer patients


    About the GEMSTONE-302 study

    GEMSTONE-302 is a multicenter, randomized, double-blind phase III clinical trial (clinicaltrials.


    In August 2020, the GEMSTONE-302 study met its prespecified primary endpoint of significantly greater efficacy in combination with chemotherapy than placebo plus chemotherapy as assessed by an independent data monitoring committee (iDMC) in a planned interim analysis.


    In July 2021, the final PFS analysis of the GEMSTONE-302 study showed that ZEJME combined with chemotherapy further enhanced the primary efficacy endpoint of progression-free survival, with a 52% reduction in the risk of disease progression or death, and demonstrated overall survival A clear trend of benefit


    About CStone

    CStone Pharmaceuticals (SEHK: 2616) is a biopharmaceutical company focused on the research, development and commercialization of innovative immuno-oncology and precision medicines to meet the high medical needs of cancer patients in China and around the world


    To learn more about CStone , please visit:.


    Forward-Looking Statements

    Forward-looking statements made herein relate only to events or information as of the date on which they are made
    .
    Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements and unanticipated events after the date on which they are made, whether as a result of new information, future events or otherwise
    .
    Please read this article carefully and understand that our actual future results or performance may differ materially from expectations
    .
    All statements in this article are made as of the date of this article and are subject to change due to future developments
    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.